These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38216032)

  • 1. Predictive Panel for Immunotherapy in Low-Grade Glioma.
    Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
    World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
    Li J; Guo Q; Xing R
    BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
    Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
    Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics analyses and experimental validation of the role of phagocytosis in low-grade glioma.
    Fei M; Lu C; Feng B; Sun J; Wang J; Sun F; Dong B
    Environ Toxicol; 2024 Apr; 39(4):2182-2196. PubMed ID: 38112449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.
    Luo X; Wang Q; Tang H; Chen Y; Li X; Chen J; Zhang X; Li Y; Sun J; Han S
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676646
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.
    Zhang G; Chen A; Fang J; Wu A; Chen G; Tai P; Chen H; Chen X; Cao K
    Front Immunol; 2023; 14():1105210. PubMed ID: 37114037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma.
    Zhang L; Qu C; Shi C; Wu F; Tang Y; Li Y; Li J; Feng H; Zhong S; Yang J; Zeng X; Peng X
    PLoS One; 2023; 18(1):e0279119. PubMed ID: 36649311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 14. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
    Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
    Front Immunol; 2022; 13():982033. PubMed ID: 36052073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Analysis of Molecular Subtypes Based on the Expression Profile of Immune-Related Genes in Pancreatic Cancer.
    Ke M
    Oxid Med Cell Longev; 2022; 2022():3124122. PubMed ID: 36567857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
    Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
    Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
    Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
    J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.